Our science

Biological complexity remains the biggest challenge in drug discovery and development. We strive to address the lack of biological understanding to unlock key unmet medical needs.

RNAi medicines are next-generation therapeutics, and their design is markedly accelerated relative to traditional drug modalities because it is based on the human genetic code.

We are progressing a broad therapeutic pipeline of GalOmic™ RNAi therapies that selectively target novel genes, guided by insights from our HepNet™ Computational Platform.

Read more about the recent articles published by our scientific leadership.